LB Pharmaceuticals, Inc. (LBRX)
37.33
-0.47
(-1.24%)
USD |
NASDAQ |
Sep 25, 16:00
37.33
0.00 (0.00%)
After-Hours: 19:59
LB Pharmaceuticals Research and Development Expense (Annual) : 16.74M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 16.74M |
| December 31, 2024 | 51.17M |
| Date | Value |
|---|---|
| December 31, 2023 | 7.845M |
| December 31, 2022 | 1.346M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Ligand Pharmaceuticals, Inc. | 81.18M |
| Neumora Therapeutics, Inc. | 176.06M |
| ANI Pharmaceuticals, Inc. | 51.66M |
| Corcept Therapeutics, Inc. | 254.91M |
| Veru, Inc. | 15.59M |